File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation

TitleHepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation
Authors
Issue Date2003
PublisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal
Citation
Leukemia And Lymphoma, 2003, v. 44 n. 8, p. 1281-1285 How to Cite?
AbstractHepatitis due to reactivation of hepatitis B virus is an important cause of liver-related morbidity and mortality in hepatitis B surface antigen (HBsAg) positive patients undergoing autologous hematopoeitic cell transplantation. With the recent introduction of sensitive serum HBV DNA quantitation assay, the diagnosis of hepatitis B reactivation can now be made more reliably. As these hepatitis are driven by the host immune response to a surge of hepatitis B viral load, the availability of effective nucleoside analogues which can inhibit hepatitis B viral replication has opened up new approaches to this previously untreatable condition. Up till now, two such nucleoside analogues, lamivudine and adefovir dipivoxil, have been approved for the treatment of chronic hepatitis B infection. However, further studies are needed to determine which nucleoside analogues should be chosen in this transplant setting. Due to the high dose chemotherapy generally needed in autologous hematopoeitic cell transplantation, there is a high risk of post-transplant hepatitis B reactivation. Hence, all HBsAg positive patients undergoing autologous hematopoeitic cell transplantation should preferably be treated pre-emptively with nucleoside analogous. An alternative approach is to defer treatment with nucleoside analogous until there is evidence of hepatitis B virological reactivation. However, the latter approach would need the patient's hepatitis B viral load be monitored at a very close interval and might not be cost-effective.
Persistent Identifierhttp://hdl.handle.net/10722/78729
ISSN
2015 Impact Factor: 3.093
2015 SCImago Journal Rankings: 1.202
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMa, SYen_HK
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorCheng, VCCen_HK
dc.contributor.authorLiang, Ren_HK
dc.date.accessioned2010-09-06T07:46:05Z-
dc.date.available2010-09-06T07:46:05Z-
dc.date.issued2003en_HK
dc.identifier.citationLeukemia And Lymphoma, 2003, v. 44 n. 8, p. 1281-1285en_HK
dc.identifier.issn1042-8194en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78729-
dc.description.abstractHepatitis due to reactivation of hepatitis B virus is an important cause of liver-related morbidity and mortality in hepatitis B surface antigen (HBsAg) positive patients undergoing autologous hematopoeitic cell transplantation. With the recent introduction of sensitive serum HBV DNA quantitation assay, the diagnosis of hepatitis B reactivation can now be made more reliably. As these hepatitis are driven by the host immune response to a surge of hepatitis B viral load, the availability of effective nucleoside analogues which can inhibit hepatitis B viral replication has opened up new approaches to this previously untreatable condition. Up till now, two such nucleoside analogues, lamivudine and adefovir dipivoxil, have been approved for the treatment of chronic hepatitis B infection. However, further studies are needed to determine which nucleoside analogues should be chosen in this transplant setting. Due to the high dose chemotherapy generally needed in autologous hematopoeitic cell transplantation, there is a high risk of post-transplant hepatitis B reactivation. Hence, all HBsAg positive patients undergoing autologous hematopoeitic cell transplantation should preferably be treated pre-emptively with nucleoside analogous. An alternative approach is to defer treatment with nucleoside analogous until there is evidence of hepatitis B virological reactivation. However, the latter approach would need the patient's hepatitis B viral load be monitored at a very close interval and might not be cost-effective.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lalen_HK
dc.relation.ispartofLeukemia and Lymphomaen_HK
dc.rightsLeukemia and Lymphoma. Copyright © Informa Healthcare.en_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshHematopoietic Stem Cell Transplantation - adverse effects - methodsen_HK
dc.subject.meshHepatitis B - diagnosis - etiology - prevention & controlen_HK
dc.subject.meshHepatitis B Surface Antigens - blooden_HK
dc.subject.meshHepatitis B virus - physiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshPremedicationen_HK
dc.subject.meshRecurrence - prevention & controlen_HK
dc.subject.meshTransplantation, Autologousen_HK
dc.subject.meshVirus Activationen_HK
dc.titleHepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1042-8194&volume=44&issue=8&spage=1281&epage=5&date=2003&atitle=Hepatitis+B+reactivation+in+patients+positive+for+hepatitis+B+surface+antigen+undergoing+autologous+hematopoietic+cell+transplantationen_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/1042819031000083343en_HK
dc.identifier.pmid12952220-
dc.identifier.scopuseid_2-s2.0-0038804139en_HK
dc.identifier.hkuros96319en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0038804139&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume44en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1281en_HK
dc.identifier.epage1285en_HK
dc.identifier.isiWOS:000183421700003-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridMa, SY=7403725725en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.scopusauthoridCheng, VCC=23670479400en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats